Page last updated: 2024-10-27

vanoxerine and Pleuropericarditis

vanoxerine has been researched along with Pleuropericarditis in 1 studies

vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.

Pleuropericarditis: Inflammation of both the PERICARDIUM and the PLEURA.

Research Excerpts

ExcerptRelevanceReference
"Vanoxerine is a promising, new, investigational antiarrhythmic drug."1.37Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results. ( Brown, AM; Cakulev, I; Khrestian, CM; Lacerda, AE; Ryu, K; Waldo, AL, 2011)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cakulev, I1
Lacerda, AE1
Khrestian, CM1
Ryu, K1
Brown, AM1
Waldo, AL1

Other Studies

1 other study available for vanoxerine and Pleuropericarditis

ArticleYear
Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.
    Journal of cardiovascular electrophysiology, 2011, Volume: 22, Issue:11

    Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac

2011